US Expects To Begin COVID-19 Vaccinations In Early December

Henrietta Strickland
November 22, 2020

Almost a million people in China have taken an experimental coronavirus vaccine through the country's emergency use program as of Wednesday, according to vaccine developer China National Pharmaceutical Group (Sinopharm).

According to details, the vaccine that is undergoing the third phase of a clinical trial in Pakistan has shown positive results with 95 percent recovery rate of the patients who were about to be shifted on a ventilator.

"In terms of emergency use, the vaccines were applied to almost a million people and there has not been a single case of a serious adverse event".

The Oxford Vaccine Group's director, Andrew Pollard, said in a media briefing there were "lots of cases" of infections in its Phase III trial in Britain, Brazil and South Africa.

On August 11, the Sputnik V vaccine was registered by the Ministry of Health of Russian Federation and became the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform. They have recruited approximately 60,000 people and blood samples of over 40,000 for their trials.

"Until now, all our progress, from research to clinical trials to production and emergency use, we have been leading the world", Jingzhen continued. Others, called viral vector, are more innovative: another virus is transformed and adapted to fight Covid-19, as in the cases of Oxford University and Russian Federation, which use adenovirus, a very common family.

But rival drugmakers Pfizer Inc, BioNTech and Moderna Inc. have in the past 10 days edged ahead, releasing data from late-stage COVID-19 vaccine trials that shows more than 90 per cent efficacy.

On November 17, Moderna, in its official statement, had announced that the independent, U.S. NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273 has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.

The developers of the world's first vaccine against coronavirus have taken to Twitter to announce that the price of Sputnik V will be much lower than that of vaccines developed by United States pharmaceutical companies Pfizer and Moderna.

While doses of the vaccine candidates are forecast to be made before the end of 2020 the firms each said global rollouts are likely to take place next year.

Sinopharm didn't respond to Newsweek's request for comment in time for publication.

Other reports by Click Lancashire

Discuss This Article